Flexion Therapeutics, Inc. (FLXN)
| Market Cap | 565.14M |
| Revenue (ttm) | 82.90M |
| Net Income (ttm) | -127.58M |
| Shares Out | 49.30M |
| EPS (ttm) | -3.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $11.44 |
| Previous Close | $11.47 |
| Change ($) | -0.03 |
| Change (%) | -0.26% |
| Day's Open | 11.50 |
| Day's Range | 10.83 - 11.55 |
| Day's Volume | 799,056 |
| 52-Week Range | 5.01 - 14.39 |
BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted st...
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021
BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after...
The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot a...
BURLINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug ...
BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...
Flexion Therapeutics Inc (NASDAQ: FLXN) plans to advance FX201 into the high dose cohort of Phase 1 dose-escalation trial, evaluating the safety and tolerability of FX201 for the treatment of ...
- Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain - Sheryl Swoopes, WNBA Legend, Basketbal...
Flexion Therapeutics recently reported their Q4 and full-year 2020 results that revealed record sales for ZILRETTA and encouraging commercial metrics. Despite the COVID-19 headwinds, the compa...
BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended Dec...
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...
BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...
BURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stoc...
BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...
BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30...
BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of th...
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET
BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will prese...
BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock...
BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will partici...
BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-esc...
BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will partici...
BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data ...
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...
BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2...
A Relative Strength Rating upgrade for Flexion Therapeutics shows improving technical performance. Will it continue?
BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent busines...
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FLXN stock has been falling because the company is not in the race for a Covid-19 vaccine. But as that field narrows, FLX is worth a look.
Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.
BURLINGTON, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA net sales of $15.4 million for the quarter ended June 30, 2...
Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BURLINGTON, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will particip...
Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
The company priced a share offering, diluting existing shareholders.
BURLINGTON, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common ...
BURLINGTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of...
Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q1 2020 Results - Earnings Call Transcript
BURLINGTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (...
BURLINGTON, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced new positive preclinical efficacy and pharmacokinetic (PK) data for FX301, its ...
Every time there is major carnage in the stock market, you see top companies trade into the single digits.
BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jian...
Flexion reported positive Q4/2019 earnings in the midst of the Coronavirus Crash. The stock has taken a nosedive to all-time lows and I am looking to take advantage.
Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q4 2019 Results - Earnings Call Transcript
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.87% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...
About FLXN
Flexion Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administere... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 12, 2014 |
| CEO Michael Clayman | Employees 288 |
| Stock Exchange NASDAQ | Ticker Symbol FLXN |
Financial Performance
In 2019, FLXN's revenue was $72.96 million, an increase of 223.91% compared to the previous year's $22.52 million. Losses were -$149.77 million, -11.72% less than in 2018.
Analyst Forecasts
According to 11 analysts, the average rating for FLXN stock is "Buy." The 12-month stock price forecast is 20.69, which is an increase of 80.86% from the latest price.